International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic dataDaniel A. Arber, Michael R. Savona, Fabio Facchetti et al.|Blood|2022Cited by 2.7k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyMax S. Topp, Hagop M. Kantarjian, Nicola Gökbuget et al.|The Lancet Oncology|2014Cited by 1.3k
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemiaMonika Brüggemann, Michael Kneba, Thorsten Raff et al.|Blood|2005Cited by 537
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantationNicola Gökbuget, Dieter Hoelzer|Blood|2012Cited by 464
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE studyHagop M. Kantarjian, Anjali S. Advani, Daniel J. DeAngelo et al.|Cancer|2019Cited by 327